![]() Algorae Pharmaceuticals Algorae Pharmaceuticals (formerly known as Living Cell Technologies Limited (LCT)) is a biotechnology company developing and commercializing treatments that use the regenerative healing properties of naturally occurring cells. | ![]() BioCryst Pharmaceuticals BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes to treat rare diseases. | Brooks Life Sciences Brooks Life Sciences is a company specializing in automated sample management for drug discovery and biostorage applications. | ![]() Aptuit Aptuit is a pharmaceutical services company that delivers early discovery to mid-phase drug development solutions. | |
Founding Date | Founding Date 1999 | Founding Date 1986 | Founding Date 1981 | Founding Date 1993 |
Type | Type Public | Type Public | Type Subsidiary | Type Subsidiary |
Tags | ||||
Locations | Locations Auckland, NZ HQ Melbourne, AU | Locations Durham, US HQ Hoover, US | Locations Greenwich, US HQ Verona, IT Reinach, CH Milton, GB | |
Employees | Employees N/A | Employees 14040% increase | Employees 5661% decrease | Employees 761 |
Valuation ($) | Valuation ($) 14.8 m | Valuation ($) 1.7 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $874.8m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $19.1m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $855.8m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($803k) (FY, 2025) | Net income $263.9m (FY, 2025) | Net income N/A | Net income N/A |

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes to treat rare diseases.
View companyBrooks Life Sciences is a company specializing in automated sample management for drug discovery and biostorage applications.
View company
Aptuit is a pharmaceutical services company that delivers early discovery to mid-phase drug development solutions.
View company